Benzinga.com

Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation

Awakn Life Sciences (OTC:AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has entered into a global licensing agreement ...
Benzinga.com

New Sublingual Psychedelic Drug Candidate Created For Depression And Anxiety In Alzheimer's

Psychedelics R&D biotech Biomind Labs Inc. BMNDF has completed the development of a novel sublingual formulation and the first production batch for testing in its Phase 2 trial on proprietary ...
Healio

Sublingual epinephrine film moving forward, NDA anticipated by early next year

Please provide your email address to receive an email when new articles are posted on . Aquestive aims to submit a new drug application in the first quarter of 2025. The company hopes to launch in ...
Business Wire

Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in ...

TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia ...
Nasdaq

Aquestive Therapeutics Successfully Demonstrates Repeatable and Predictable Oral Sublingual Film Administration of Epinephrine

WARREN, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address ...
The Journal News

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial ...

ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, ...
Nasdaq

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement ...

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
Medscape

Subcutaneous Versus Sublingual Immunotherapy for Allergic Rhinitis and/or Asthma

Subcutaneous allergen-specific immunotherapy has long been used in allergic rhinitis and/or asthma and has been recognized to be efficacious. However, owing to the inconvenience of injection and the ...
Seeking Alpha

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial ...

TxB2 is a biomarker indicating aspirin's effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots This rapid inhibition is critical during suspected heart attacks, ...